Nivolumab Gets FDA Nod for Bladder Cancer.
The FDA has granted accelerated approval to nivolumab for patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed on platinum chemotherapy. This is the second PD-1-targeting agent in less than a year to get the agency's nod for bladder cancer.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors / Q000235:genetics*; D014481:United States; D014486:United States Food and Drug Administration; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab